APA (7th ed.) Citation

M, N., U, H., UE, B., B, F., D, A., KE, S., . . . GJ, F. (2013). CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer immunology, immunotherapy : CII, 62(2), 347. https://doi.org/10.1007/s00262-012-1331-4

Chicago Style (17th ed.) Citation

M, Naito, et al. "CD40L-Tri, a Novel Formulation of Recombinant Human CD40L That Effectively Activates B Cells." Cancer Immunology, Immunotherapy : CII 62, no. 2 (2013): 347. https://doi.org/10.1007/s00262-012-1331-4.

MLA (9th ed.) Citation

M, Naito, et al. "CD40L-Tri, a Novel Formulation of Recombinant Human CD40L That Effectively Activates B Cells." Cancer Immunology, Immunotherapy : CII, vol. 62, no. 2, 2013, p. 347, https://doi.org/10.1007/s00262-012-1331-4.